

Bod is a cannabis centric healthcare company. With a global focus and a mission to innovate and transform the way we live and enjoy life. Delivering premium, proven and trusted products for both the consumer markets and medical markets. Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications with education, research and knowledge.

#### CAPITAL STRUCTURE

ASX code **BDA**  
 Shares on issue 91.4m  
 Market Capitalisation ~\$28.3m

#### BOARD & MANAGEMENT

Mr Mark Masterson  
 Non-Executive Chairman

Ms Jo Patterson  
 Chief Executive Officer

Mr Akash Bedi  
 Non-Executive Director

Mr George Livery  
 Non-Executive Director

Mr Patrice Malard  
 Non-Executive Director

Mr Simon O'Loughlin  
 Non-Executive Director

Mr Stephen Kelly  
 Company Secretary

#### CONTACT

Level 1, 377 New South Head Rd  
 Double Bay, NSW 2028

T +612 9199 5018

E [info@bodaustralia.com.au](mailto:info@bodaustralia.com.au)

## First medical cannabis prescriptions received from UK patients participating in Project Twenty21

- **Bod is one of five companies and the only Australian company participating in Project Twenty21 – Europe’s largest medicinal cannabis registry targeting 20,000 patients**
- **Participation provides additional sales channel in the UK and builds brand awareness amongst patients, physicians and clinics on a national scale**
- **Bod expects to facilitate a minimum of 1,000 prescriptions from Project Twenty21 and will be receiving revenue for MediCabilis™ prescription received from patients**
- **MediCabilis™ to be sold at £150 per unit during the project – adds to growing revenue profile**
- **UK cannabis market is estimated to grow to \$3Bn in value by 2024<sup>i</sup> and 4 times the size of the Australian market by 2028<sup>ii</sup> – providing significant opportunity for Bod**

**Sydney, Australia – 11 May 2020:** Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) is pleased to confirm excellent progress in the United Kingdom market, with first prescriptions for the Company’s MediCabilis™ medicinal cannabis product received from UK patients participating in Project 21. Project Twenty21, is Europe’s largest medicinal cannabis registry, targeting 20,000 patients.

Bod expects to supply a minimum of 1,000 patients during the registry with its unique 5% MediCabilis™ CBD product. MediCabilis™ will be sold for £150.00 per unit during Project Twenty21, which will add to Bod’s growing revenue profile. The registry is expected to conclude at the end of 2021 but may continue into 2022 due to current conditions.

Now that the registry has commenced, a broad range of physicians and clinics across the UK can prescribe Bod’s MediCabilis™ to patients participating in Project Twenty21. This is a major milestone for the Company as it provides Bod with an additional sales channel for MediCabilis™.

Project Twenty21 is a UK centric registry, which will generate the largest body of evidence for the efficacy of medicinal cannabis. It aims to utilise collected data to convince policy makers that medicinal cannabis should be made more readily available, and affordable, for patients who would benefit from its use. The project will also assist prescribers in their treatment of patients in the UK and advance the potential for NHS funding.

The registry intends on reaching 20,000 patients suffering from conditions including chronic pain, Multiple Sclerosis, Post-Traumatic Stress Disorder (PTSD), Tourette’s Syndrome, Anxiety disorders and issues arising from substance abuse.

Commencement of Project Twenty21 will deliver positive growth in MediCabilis™ prescription volumes in the UK and will help Bod achieve greater critical mass in what is a large addressable market – set to become four times the size of the Australian market in the coming years.

Participation in the study provides Bod with another sales channel in the United Kingdom, which will complement other growth strategies in the country. Bod recently received its first prescriptions from patients in the UK from private practice (refer ASX announcement: 4 May 2020) and expects to witness ongoing growth in the country as brand awareness grows with physicians, clinics and patients.

**CEO Jo Patterson said:** “The commencement of Project Twenty21 is a major development for Bod and provides the Company with another opportunity to grow in a market estimated to be worth \$3Bn by 2024.

“Participation in the registry opens another sales avenue for MediCabilis™ and will provide the Company with exposure to a large number of physicians, patients and clinics across the country. This is pivotal as Bod continues to build brand awareness across the UK.

“We are confident that the UK will be an important growth market for MediCabilis™ and these initial patients provide the beginning of what will become a scalable revenue base for the Company.

- ENDS -

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** Bod is a cannabis centric healthcare company.

With a global focus and a mission to innovate and transform the way we live and enjoy life.

Delivering premium, proven and trusted products for both the consumer markets and medical markets.

Leading the way in research and development, through collaborations with research partners on clinical trial programs.

Committed to supporting the healthcare professional on Cannabinoid applications through education, research and trials.

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538

<sup>i</sup> The UK Cannabis Report – December 2019 – Prohibition Partners

<sup>ii</sup> The European Cannabis Report, 4<sup>th</sup> Edition 2019 – Prohibition Partners